Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status

Wen‐Zhao Zhong(Guangdong Academy of Medical Sciences), Yi‐Long Wu(Guangdong Academy of Medical Sciences)

Journal of Hematology & Oncology

May 16, 2015

10.1186/s13045-015-0151-3

Cited by 89

Related Papers

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

|New England Journal of Medicine|2009|8.2k

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

|The Lancet Oncology|2011|4.1k

Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer

|New England Journal of Medicine|2013|3.4k

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

|The Lancet|2019|3.3k

Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer

|New England Journal of Medicine|2016|3.3k